ACCESS Newswire

ZAGENO

25.5.2023 14:01:43 CEST | ACCESS Newswire | Press release

Share
ZAGENO Secures $33M Funding to Revolutionize Life Science Research Procurement

ZAGENO Empowers Life Science Research with Unparalleled Efficiency and Cost Savings

CAMBRIDGE, MA / ACCESSWIRE / May 25, 2023 / ZAGENO, the leading online marketplace for life science research products, announces the completion of a $33 million funding round. General Catalyst, the largest public pension fund in the United States, Grazia Equity, OakRidge Management Group, and a German investment house led this round, joined by existing investors Capnamic Ventures and HighSage Ventures.

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
Logo


This funding propels ZAGENO's expansion in the United States and Europe, significantly enhancing the accessibility and affordability of life science research products. ZAGENO simplifies product discovery, experiment planning, and seamless purchasing from thousands of suppliers. The marketplace revolutionizes the scientific workflow, saving time and product costs. With a wide selection of quality products and verified suppliers, scientists benefit from competitive pricing fostered by the marketplace's transparency and supplier choice.

"We're thrilled to welcome new investors, including one of America's most powerful shareholder bodies and global leader in the investment industry and a prominent German investment house, while enjoying continued support from General Catalyst and existing investors," said Florian Wegener, CEO of ZAGENO. "This funding empowers scientists to focus on scientific value creation."

ZAGENO's online marketplace offers a vast selection of products and services, including laboratory equipment, consumables, chemicals, antibodies, and customized solutions. By providing scientists access to a network of verified suppliers, the ZAGENO platform enables informed purchasing decisions.

"ZAGENO is transforming the scientific research industry with its groundbreaking platform," said Larry Bohn, Managing Partner at General Catalyst. "We proudly support their journey."

"With this funding, ZAGENO is positioned to deliver even greater value to scientists worldwide," emphasized Joe von Rickenbach, Chairman of the Board of ZAGENO. "Their innovative platform drives unmatched efficiency and cost savings."

ZAGENO is primed for rapid growth and pioneering innovation in the scientific research industry with this new funding.

To learn more about ZAGENO, please visit www.zageno.com.

About ZAGENO

ZAGENO is a marketplace for life science research products. By revolutionizing how scientists discover, procure, and manage life science research products, ZAGENO supports researchers pursuing breakthroughs that improve our lives. With an extensive catalog, advanced search functionality, transparent pricing, and dedicated customer support, ZAGENO simplifies the research workflow and enables scientists to focus on groundbreaking discoveries. ZAGENO is a global company with offices in Cambridge, San Francisco, Berlin, and Bangalore. For more information, visit www.zageno.com.

About General Catalyst

General Catalyst is a venture capital firm that invests in powerful, positive change that endures - for our entrepreneurs, our investors, our people, and society. We support founders with a long-term view who challenge the status quo, partnering with them from seed to growth stage and beyond to build companies that withstand the test of time. With offices in San Francisco, Palo Alto, New York City, London, and Boston, the firm has helped support the growth of businesses such as: Airbnb, Deliveroo, Guild, Gusto, Hubspot, Illumio, Lemonade, Livongo, Oscar, Samsara, Snap, Stripe, and Warby Parker. For more: www.generalcatalyst.com.

Contact Information

Stephanie Harold
pr@zageno.com
+1 (857) 477-8479

Related Files

ZAGENO.png

Related Images

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
Logo
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
Product

SOURCE: ZAGENO

To view this piece of content from stats.newswire.com, please give your consent at the top of this page.

View source version on accesswire.com:
https://www.accesswire.com/757107/ZAGENO-Secures-33M-Funding-to-Revolutionize-Life-Science-Research-Procurement

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

Clean Air Metals and Fiore-backed Springbok Ventures Announce Upsize of Non-Brokered Private Placement10.8.2026 20:30:00 CEST | Press release

Not for distribution to United States newswire services or for dissemination in the United States. THUNDER BAY, ON / ACCESS Newswire / August 10, 2026 / Clean Air Metals Inc. ("Clean Air Metals") (TSX.V:AIR)(FRA:CKU)(OTCQB:CLRMF) and Springbok Ventures Inc. ("Springbok") are pleased to announce that, further to the joint news release dated August 1, 2026, due to strong market demand they have agreed to increase the size of the previously announced non-brokered private placement of subscription receipts (the "Offering") to $6.1 million, as follows: 10,000,000 subscription receipts of Springbok (the "Springbok Subscription Receipts") at a price of $0.50 per Springbok Subscription Receipt; and 2,000,000 subscription receipts of Clean Air Metals (the CAM Subscription Receipts") at a price of $0.55 per CAM Subscription Receipt. Each Springbok Subscription Receipt will, subject to satisfaction or waiver of certain escrow release conditions, automatically convert in accordance with its terms

ABL Ascend Advanced Therapies Names Suman Subramanian as Chief Business Officer10.8.2026 10:00:00 CEST | Press release

ROCKVILLE, MD / ACCESS Newswire / August 10, 2026 / ABL Inc and Ascend Advanced Therapies today announced the appointment of Suman Subramanian as Chief Business Officer (CBO), further strengthening the Company's commercial leadership and its commitment to supporting customers with the development and manufacturing of viral vectors, vaccines, biologics and advanced therapies. Suman brings nearly two decades of experience and leadership, supporting emerging biotech and large pharma within the biopharmaceutical industry. He will be responsible for leading the company's global commercial organization, including business development, marketing and strategic partnership functions. As the industry continues to evolve, customers are now increasingly seeking end-to-end CDMO partners capable of translating science and delivering impeccable service whilst reducing technical, operational and manufacturing risks. Through his experience with programs ranging from early-stage development to commercia

Innodata Reports Record Second Quarter 2026 Results6.8.2026 22:05:00 CEST | Press release

Revenue Up 58% Year-Over-Year, Beats Consensus by 7% Adjusted EBITDA of $25.4 Million, Beats Consensus by 50% Adjusted Gross Margin Expands to 49% Announces Planned Leadership Transition Effective September 30: Rahul Singhal to Become President and CEO, Jack Abuhoff to Become Executive Chairman NEW YORK, NY / ACCESS Newswire / August 6, 2026 / INNODATA INC. (NASDAQ:INOD) today reported results for the second quarter ended June 30, 2026. Revenue of $92.1 million, representing 58% year-over-year revenue growth. Adjusted Gross Profit of $45.4 million, representing Adjusted Gross Margin of 49%.* Adjusted EBITDA of $25.4 million, or 27.5% of revenue, an increase of $12.1 million from $13.2 million in the same period last year.* Net income of $14.4 million, or $0.43 per basic share and $0.41 per diluted share for the three-month period ended June 30, 2026, compared to net income of $7.2 million, or $0.23 per basic share and $0.20 per diluted share, in the same period last year. Cash, cash eq

Loar Holdings Inc. Reports Q2 2026 Record Results and Upward Revision to 2026 Outlook6.8.2026 14:30:00 CEST | Press release

WHITE PLAINS, NY / ACCESS Newswire / August 6, 2026 / Loar Holdings Inc. (NYSE:LOAR) (the "Company," "Loar," "we," "us" and "our") reported record results for the second quarter of 2026. "Through the first half of the year, the business continues to outperform our expectations, driven by exceptional demand across our end-markets and strong conversion of our new business pipeline. Of the approximately $750 million in our pipeline, we secured initial orders that provide visibility to approximately $200 million of revenue over the next five years," said Dirkson Charles, Loar Holdings Chief Executive Officer and Executive Co-Chairman of the Board of Directors. Second Quarter 2026 Net sales of $171.6 million, up 39.4% compared to the prior year's quarter. Net income of $16.7 million, equal to the prior year's quarter. Diluted earnings per share of $0.18 compared to $0.17 for the prior year's quarter. Adjusted EBITDA of $69.4 million up 47.4% compared to the prior year's quarter. Net income

RE Royalties Announces Third Investment in Solaris Energy's Portfolio and Letter of Intent for Expanded Royalty Partnership for a Further US$62.7 Million5.8.2026 12:00:00 CEST | Press release

All amounts in US dollars unless otherwise stated. VANCOUVER, BC / ACCESS Newswire / August 5, 2026 / RE Royalties Ltd. (TSXV:RE)(OTCQX:RROYF)(FSE:Y2V) ("RE Royalties" or the "Company") is pleased to announce a further investment of US$1 million toward the purchase of royalties on a portfolio of Solaris Energy Inc.'s ("Solaris") distributed generation ("DG") solar projects located throughout the United States. The Company also announced that it has entered into a non-binding Letter of Intent ("LOI") of up to US$67.5 million with Solaris to pursue an expanded royalty funding partnership across Solaris' current and future project pipeline. This third tranche payment brings RE Royalties' total investment in royalties over Solaris' portfolio to US$4.8 million. The Company previously funded US$3 million, as announced on January 7, 2026, followed by US$800,000 as announced on February 9, 2026. Solaris' Portfolio consists of 16 distributed generation solar projects totaling approximately 15.2

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye